Use of Oral Dicholoracetate (DCA) for Palliation in Cancer

Use of Oral Dicholoracetate (DCA) for Palliation in Cancer

Akbar Khan, M.D.

MRI showing right calf tumor (single arrow) and subcutaneous edema (double arrow) CT after 5 months of DCA therapy showing stable right calf tumor and absence of calf edema
Left: MRI showing right calf tumor (single arrow) and subcutaneous edema (double arrow)
Right: CT after 5 months of DCA therapy showing stable right calf tumor and absence of calf edema

Abstract
Dicholoracetate sodium (DCA) is a nonproprietary drug currently used for treatment of inherited mitochondrial diseases. It was discovered in 2007 that DCA promotes human cancer cell death by a novel mechanism. Soon after this discovery, physicians began using DCA off-label for cancer treatment in a palliative setting. A case report is presented of a 71-year-old male with poorly differentiated carcinoma of unknown primary metastatic to the right leg and liver who achieved excellent palliation of leg pain by using oral DCA after failing conventional
therapy.

Full Article:

Use of Oral Dicholoracetate for Palliation of Leg Pain Arising from Metastatic Poorly Differentiated Carcinoma: A Case Report

http://www.liebertonline.com/doi/pdfplus/10.1089/jpm.2010.0472

One thought on “Use of Oral Dicholoracetate (DCA) for Palliation in Cancer

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top